Associate
Omeed Valipour advises public and private companies on corporate and securities law matters, with an emphasis on public and private financings for companies in the healthcare and life sciences industry. He also regularly represents underwriters and financial institutions in securities offerings.
Dr. Valipour draws on his comprehensive understanding of capital markets transactions and his unique background in pharmaceutical sciences to take a pragmatic approach to guide biotechnology and other life sciences companies at every stage of their life cycle, including:
He earned his PharmD from UC San Diego, where his clinical and scientific research focused on neuropharmacology and pharmacological drug metabolite predictors of disease pathogenesis and drug responsiveness. Dr. Valipour’s research incorporated a broad variety of techniques, including those used in cellular and molecular biology, physiology and pharmacology. As a result of his graduate and undergraduate training, Dr. Valipour has a deep understanding of pathophysiology and pharmacology.
Dr. Valipour keenly understands the capital markets implications for healthcare and life sciences companies and distills complex scientific and legal jargon into actionable client advice. He builds trusted, long-term relationships to help clients navigate high-stakes transactions and strategize solutions on day-to-day corporate issues that arise.
Dr. Valipour has represented companies and underwriters in initial public offerings, private and public financings, and mergers and acquisitions, including:
Chambers USA recognized the firm as a “powerhouse in the capital markets space.”